Novartis AG
NLRP MODULATORS

Last updated:

Abstract:

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to treat connected to the modulation of NRLP3. ##STR00001##

Status:
Application
Type:

Utility

Filling date:

2 Jul 2019

Issue date:

25 Aug 2022